ABSTRACT
Seeds of industrial hemp (Cannabis sativa L.) contain a large amount of protein (26.3%), dietary fiber (27.5%), and fatty acids (33.2%), including linoleic, α-linolenic, and some amount of γ-linolenic acid. In our study, obese male Zucker rats (n = 6) at 8 weeks of age were supplemented for a further 4 weeks with either ground hemp seeds (12% diet) or lipid fractions in the form of hemp seed oil (4% diet). Hemp oil decreased blood plasma HDL-cholesterol (x0.76, p ≤ 0.0001), triglycerides (x0.55, p = 0.01), and calculated atherogenic parameters. Meanwhile, hemp seeds decreased HDL-cholesterol (x0.71, p ≤ 0.0001) and total cholesterol (x0.81, p = 0.006) but not the atherogenic index. The plasma antioxidant capacity of water-soluble compounds was decreased by the seeds (x0.30, p = 0.0015), which in turn was associated with a decrease in plasma uric acid (x0.18, p = 0.03). Dietary hemp seeds also decreased plasma urea (x0.80, p = 0.02), while the oil decreased the plasma total protein (x0.90, p = 0.05). Hemp seeds and the oil decreased lipid peroxidation in the blood plasma and in the heart (reflected as malondialdehyde content), improved contraction to noradrenaline, and up-regulated the sensitivity of potassium channels dependent on ATP and Ca2+. Meanwhile, acetylcholine-induced vasodilation was improved by hemp seeds exclusively. Dietary supplementation with ground hemp seeds was much more beneficial than the oil, which suggests that the lipid fractions are only partially responsible for this effect.
Subject(s)
Cannabis , Cardiovascular Physiological Phenomena , Dietary Supplements , Obesity/physiopathology , Plant Extracts , Seeds , Animals , Antioxidants , Blood Glucose , Blood Pressure , Blood Proteins/analysis , Lipid Peroxidation , Lipids/blood , Male , Myocardium/metabolism , Rats , Rats, Zucker , Thromboxane A2/analysis , Vasoconstriction , VasodilationABSTRACT
Hypertension is one of the most common complications of chronic kidney disease (CKD). Some research has indicated that changes in large artery function especially caused by thromboxane A2 (TXA2) may be a novel factor acting to induce hypertension in CKD. We studied the 5/6 nephrectomy rat model and measured serum levels of creatinine (Cr), calcium (Ca), phosphorus (P), TXA2-stable metabolites (thromboxane B2, TXB2), and caudal artery pressure after nephrectomy. The tension variations in thoracic aortas were measured after stimulating by vasoconstrictor/vasodilator using the cumulative concentration administration method and then tested the expression of TXA2 receptors in the thoracic aortas through western blots. The CKD rats developed uremia, electrolyte imbalancesï¼and hypertension. They also exhibited a significant increase in TXB2 concentration. The aortic rings of CKD rats showed an increased contraction response to U46619 (a TXA2 analogue) and the expression of TXA2 receptors also enhanced. In the meanwhile, the diastolic function decreased in the CKD group. Our results demonstrate that the impairment of artery contractile function caused by the increase of TXA2 receptors on the wall of aortic rings may be involved in hypertension in CKD rats.
Subject(s)
Hypertension/pathology , Receptors, Thromboxane/metabolism , Renal Insufficiency, Chronic/complications , Thromboxane A2/metabolism , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/pathology , Aorta, Thoracic/physiopathology , Disease Models, Animal , Humans , Hypertension/etiology , Hypertension/physiopathology , Male , Rats , Receptors, Thromboxane/analysis , Thromboxane A2/analysis , Vasoconstriction/drug effects , Vasoconstriction/physiology , Vasoconstrictor Agents/pharmacologyABSTRACT
The adherence and shear-resistance of human umbilical venous endothelial cells (HUVEC) on polymers is determined in vitro in order to qualify cardiovascular implant materials. In these tests, variable fractions of HUVEC do not adhere to the material but remain suspended in the culture medium. Nonadherent HUVEC usually stop growing, rapidly lose their viability and can release mediators able to influence the growth and function of the adherent HUVEC. The aim of this study was the investigation of the time dependent behaviour of HUVEC under controlled nonadherent conditions, in order to gain insights into potential influences of these cells on their surrounding environment in particular adherent HUVEC in the context of in vitro biofunctionality assessment of cardiovascular implant materials. Data from adherent or nonadherent HUVEC growing on polystyrene-based cell adhesive tissue culture plates (TCP) or nonadhesive low attachment plates (LAP) allow to calculate the number of mediators released into the culture medium either from adherent or nonadherent cells. Thus, the source of the inflammatory mediators can be identified. For nonadherent HUVEC, a time-dependent aggregation without further proliferation was observed. The rate of apoptotic/dead HUVEC progressively increased over 90% within two days. Concomitant with distinct blebbing and loss of membrane integrity over time, augmented releases of prostacyclin (PGI2, up to 2.91 ± 0.62 fg/cell) and platelet-derived growth factor BB (PDGF-BB, up to 1.46 ± 0.42 fg/cell) were detected. The study revealed that nonadherent, dying HUVEC released mediators, which can influence the surrounding microenvironment and thereby the results of in vitro biofunctionality assessment of cardiovascular implant materials. Neglecting nonadherent HUVEC bears the risk for under- or overestimation of the materials endothelialization potential, which could lead to the loss of relevant candidates or to uncertainty with regard to their suitability for cardiac applications. One approach to minimize the influence from nonadherent endothelial cells could be their removal shortly after observing initial cell adhesion. However, this would require an individual adaptation of the study design, depending on the properties of the biomaterial used.
Subject(s)
Cell Adhesion/physiology , Cell Culture Techniques , Human Umbilical Vein Endothelial Cells/cytology , Apoptosis , Cell Culture Techniques/instrumentation , Cell Culture Techniques/methods , Cell Death , Cell Division , Culture Media, Conditioned/chemistry , Cytokines/analysis , Epoprostenol/analysis , Human Umbilical Vein Endothelial Cells/drug effects , Humans , Inflammation Mediators/analysis , Intercellular Signaling Peptides and Proteins/analysis , L-Lactate Dehydrogenase/analysis , Polystyrenes , Recombinant Proteins/pharmacology , Surface Properties , Thromboxane A2/analysis , Tumor Necrosis Factor-alpha/pharmacologyABSTRACT
Merlot are worldwide recognized red wines. Several studies show that red wines have health benefits, mainly due to their phenolic constituents. This study evaluates twelve Serbian and other five European (French, Italian, Macedonian, Slovenian, Spanish) Merlot wines in respect of their phenolic composition and biological activity. The latter was evaluated through a set of in vitro experiments related to common benefits of moderate red wine consumption in the prevention of cardiovascular diseases. Among the examined phenolics, the most abundant acid in all samples was the gallic acid (14.3-58.3â¯mg/L), catechin (9.1-49.3â¯mg/L) was the dominant flavonoid, malvidin-3-O-glucoside (2.63-66.5â¯mg/L) leading anthocyanin, whereas resveratrol was found in a usual concentration (0.18-4.67â¯mg/L). Differences determined in phenolic profiles, mainly in content of quercetin, rutin and p-coumaric acid, leaded to separation of Serbian from foreing Merlot wines. Results of standard antioxidant assays (DPPHâ¢, ABTSâ¢+ and â¢NO scavenger capacity reducing power (FRAP), lipid peroxidation) revealed French Merlot as the most potent, but also pointed out some Serbian samples. The correlation between the content of dominant phenolics and antioxidant activity was sporadic, but samples with the highest overall phenolic content, generally had higher antioxidant potential. Concentration of wines and number of cells in ant-inflammatory assay were chosen to mimic in vivo conditions. So, the potency of examined wines to decrease the production of macrophage-derived PGE2 and TXA2 (up to 65.5 and 47.9%, respectively), could be considered as in vitro evidence of positve health effect. Regarding the phenolic content and anti-inflammatory contribution of the most abundant compounds, no correlation was witnessed. In general, this study showed interesting potential of Serbian Merlot wines, comparable to health-promoting effects of renewed Eurepean ones.
Subject(s)
Anti-Inflammatory Agents/analysis , Antioxidants/analysis , Inflammation/metabolism , Wine/analysis , Cell Line, Tumor , Dinoprostone/analysis , Dinoprostone/metabolism , Flavonoids/analysis , Humans , Macrophages/drug effects , Macrophages/metabolism , Oxidation-Reduction , Phenols/analysis , Thromboxane A2/analysis , Thromboxane A2/metabolismABSTRACT
Our group has previously shown that αB-crystallin (HSPB5), a small heat shock protein, inhibits human platelet aggregation by ristocetin, an activator of glycoprotein Ib/IX/V. In addition, it was demonstrated that glycoprotein Ib/IX/V activation induces soluble CD40 (sCD40) ligand release via thromboxane (TX) A2. In the present study, the effect of αB-crystallin on the ristocetin-induced sCD40 ligand release in human platelets was investigated. The ristocetin-induced release of sCD40 ligand was suppressed by αB-crystallin. In addition, αB-crystallin reduced the ristocetin-stimulated production of 11-dehydro-TX B2, a stable metabolite of TXA2. αB-crystallin did not suppress the platelet aggregation induced by U46619, a TXA2 receptor agonist. αB-crystallin had little effect on the U46619-induced phosphorylation of p38 mitogen-activated protein kinase or sCD40 ligand release. In addition, αB-crystallin failed to reduce the binding of SZ2, a monoclonal antibody against the sulfated sequence in the α-chain of glycoprotein Ib, to the ristocetin-stimulated platelets. These results strongly suggest that αB-crystallin extracellularly suppresses ristocetin-stimulated release of sCD40 ligand by inhibiting the TXA2 production in human platelets.
Subject(s)
Anti-Bacterial Agents/toxicity , Blood Platelets/drug effects , CD40 Ligand/metabolism , Ristocetin/toxicity , Thromboxane A2/metabolism , alpha-Crystallin B Chain/pharmacology , 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/toxicity , Adult , Antibodies, Monoclonal/immunology , Blood Platelets/cytology , Blood Platelets/metabolism , CD40 Ligand/analysis , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Phosphorylation/drug effects , Platelet Aggregation/drug effects , Thromboxane A2/analysis , alpha-Crystallin B Chain/immunology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Phosphatidylinositol trisphosphate (PIP3) has been implicated in many platelet functions however many of the mechanisms need clarification. We have used cell permeable analogues of PIP3,1-O-(1,2-di-palmitoyl-sn-glyero-3-O-phosphoryl)-D-myo-inositol-3,4,5-trisphosphate (DiC16-PIP3) or 1-O-(1,2-di-octanoyl-sn-glyero-3-O-phosphoryl)-D-myo-inositol-3,4,5-trisphosphate (DiC8-PIP3) to study their effects on activation on washed human platelets. Addition of either DiC8- or DiC16-PIP3 to human platelets induced aggregation in the presence of extracellular Ca(2+). This was reduced by the presence of indomethacin, the phospholipase C inhibitor U73122 and apyrase. DiC8-PIP3 induced the phosphorylation of Akt-Ser(473) which was reduced by the Akt inhibitor IV, wortmannin and EGTA (suggesting a dependence on Ca(2+) entry). In Fura2 loaded platelets DiC8-PIP3 was effective at increasing intracellular Ca(2+) in a distinct and transient manner that was reduced in the presence of indomethacin, U73122 and 2-aminoethyl diphenylborinate (2APB). Ca(2+) elevation was reduced by the non-SOCE inhibitor LOE908 and also by the SOCE inhibitor BTP2. DiC8-PIP3 induced the release of Ca(2+) from stores which was not affected by the proton dissipating agent bafilomycin A1 and was more potent than the two-pore channel agonist DiC8-PI[3,5]P2 suggesting release from an endoplasmic reticulum type store. DiC8-PIP3 weakly induced the tyrosine phosphorylation of Syk but not of PLCγ2. Finally like thrombin DiC8-PIP3 induced the formation of thromboxane B2 that was inhibited by the Akt inhibitor IV. These studies suggest that PIP3 via Ca(2+) elevation and Akt phosphorylation forms a central role in thromboxane A2 formation and the amplification of platelet activation.
Subject(s)
Blood Platelets/drug effects , Calcium/metabolism , Phosphatidylinositol Phosphates/pharmacology , Proto-Oncogene Proteins c-akt/metabolism , Thromboxane A2/metabolism , Androstadienes/pharmacology , Blood Platelets/cytology , Blood Platelets/metabolism , Egtazic Acid/pharmacology , Enzyme-Linked Immunosorbent Assay , Fura-2/chemistry , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Phospholipase C gamma/antagonists & inhibitors , Phospholipase C gamma/metabolism , Phosphorylation/drug effects , Platelet Aggregation/drug effects , Protein Kinase Inhibitors/pharmacology , Protein-Tyrosine Kinases/metabolism , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Syk Kinase , Thromboxane A2/analysis , WortmanninABSTRACT
BACKGROUND: Platelets contain an array of biologic mediators that can modulate inflammation and repair processes including proinflammatory mediators and growth factors. Previous studies have shown that periodontitis and periodontal repair are associated with platelet activation. We hypothesized that drug-induced platelet inactivation may interfere in the processes of inflammation and repair in experimental periodontitis in rats by suppressing the release of biologic mediators from platelets to the site of injury. METHODS: To measure the effects on periodontitis, ligatures were placed around first molars, and aspirin (Asp, 30 mg/kg) or clopidogrel (Clo, 75 mg/kg) was given intragastrically once daily for 15 days. Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and thromboxane A(2) levels were measured by enzyme-linked immunosorbent assay. To evaluate the effects of antiplatelet drugs on periodontal repair, ligatures were removed after 15 days of periodontitis induction, and Asp or Clo were administered beginning the following day for 15 days. Periodontal repair was assessed by microcomputed tomography. RESULTS: On periodontitis phase, Asp and Clo significantly reduced levels of TNF-α and Il-6 (P <0.05), but only Asp decreased thromboxane A(2) (P <0.05). Asp and Clo decreased inflammatory infiltration; however, this reduction was more pronounced with Clo treatment (P <0.05). Histometric analysis showed that Asp and Clo impaired alveolar bone resorption. During the repair phase and after removal of the ligatures, microcomputed tomography analysis demonstrated that treatment with Asp and Clo did not impair alveolar bone repair. CONCLUSION: Systemic administration of Asp and Clo attenuates the inflammation associated with periodontitis without affecting the repair process when stimulus is removed.
Subject(s)
Periodontitis/etiology , Periodontium/drug effects , Platelet Aggregation Inhibitors/therapeutic use , Alveolar Bone Loss/etiology , Alveolar Bone Loss/pathology , Alveolar Bone Loss/prevention & control , Animals , Aspirin/therapeutic use , Blood Platelets/drug effects , Bone Density/drug effects , Bone Regeneration/drug effects , Clopidogrel , Inflammation Mediators/analysis , Intercellular Signaling Peptides and Proteins/analysis , Interleukin-6/analysis , Leukocytes/drug effects , Male , Mandibular Diseases/etiology , Mandibular Diseases/pathology , Mandibular Diseases/prevention & control , Periodontal Attachment Loss/etiology , Periodontal Attachment Loss/pathology , Periodontal Attachment Loss/prevention & control , Periodontitis/pathology , Periodontitis/prevention & control , Periodontium/pathology , Platelet Activation/drug effects , Random Allocation , Rats , Rats, Sprague-Dawley , Thromboxane A2/analysis , Ticlopidine/analogs & derivatives , Ticlopidine/therapeutic use , Time Factors , Tumor Necrosis Factor-alpha/drug effects , Wound Healing/drug effects , X-Ray MicrotomographyABSTRACT
INTRODUCTION: In South Africa coronary artery disease (CAD) is less common in African than Indian or white subjects. Although the association between CAD and metabolic factors have been well documented, the role of genetic factors is as yet poorly understood. Specific polymorphisms in the platelet membrane glycoprotein (GP) IIIa gene Pl(A1/A2), have been implicated in the development of CAD. METHODS: The prevalence of platelet GPIIIa (Pl(A1/A2)) polymorphisms and their effect on platelet function was determined in 313 Indian, 267 white and 227 African subjects with and without a history of CAD. RESULTS: In subjects without a history of CAD the frequency of the unfavourable Pl(A2) allele was 8.0%, 14.8% and 8.7% in the Indian, white and African populations respectively, with the frequency being significantly higher (p<0.05) in the white than both other groups. The frequency of the Pl(A2) allele was higher in subjects with (23.0%) than without (10.0%; p<0.0001) a history of CAD. Aggregation studies showed that platelets carrying the Pl(A2) allele were hypersensitive to the platelet aggregating agonists ADP and collagen and produced a higher amount of TXA(2) when stimulated with low concentrations of both these agonists. CONCLUSIONS: The positive association observed between the platelet GPIIIa Pl(A1/A2) polymorphism and platelet function suggests that the GPIIIa Pl(A2) allele may be a genetic factor that contributes to the risk of sudden death from myocardial infarction in the absence of known risk factors but it does not explain ethnic differences in the prevalence of CAD.
Subject(s)
Blood Platelets/metabolism , Ethnicity/genetics , Integrin beta3/genetics , Polymorphism, Genetic , Adenosine Diphosphate/agonists , Adenosine Diphosphate/pharmacology , Alleles , Collagen/agonists , Collagen/pharmacology , Coronary Artery Disease/genetics , Coronary Artery Disease/metabolism , Dose-Response Relationship, Drug , Female , Gene Frequency , Genotype , Humans , Male , Platelet Aggregation/physiology , Prevalence , South Africa/ethnology , Thromboxane A2/analysis , Thromboxane A2/biosynthesis , Thromboxane A2/metabolism , Urban PopulationABSTRACT
AIM OF THE STUDY: Actinostemma lobatum Maxim, a wildlife plant of Cucurbitaceae family, has been utilized for the prevention or treatment of cardiovascular diseases as a folk remedy in Korea. However, its scientific evidence remains unclear. Thus, in the present study, we examined the effects of butanol fraction of Actinostemma lobatum Maxim (BFALM) on the in vitro and in vivo antithrombotic activity and possible mechanisms were elucidated for the first time. MATERIAL AND METHODS: To elucidate the antithrombotic mechanism of BFALM, platelet aggregation assay, coagulation assay, glycoprotein IIb/IIIa assay, thromboxane A(2) assay and in vivo pulmonary thromboembolism experiment were performed. RESULTS: BFALM significantly inhibited collagen, adenosine diphosphate (ADP) and thrombin-induced platelet aggregation in a concentration dependent manner. Consistently, oral administration of BFALM resulted in a dose-dependent increase of survival rates of mice with pulmonary thromboembolism induced by intravenous injection of collagen and epinephrine. In mechanism assays for the antithrombotic activity of BFALM, BFALM significantly inhibited the fibrinogen binding to the platelet surface Glycoprotein IIb/IIIa (GP IIb/IIIa) receptor in a concentration dependent fashion, as well as reduced the level of thromboxane A(2) at 400microg/ml. Furthermore, BFALM significantly prolonged the prothrombin time (PT) and activated partial thromboplastin time (APTT) compared with untreated control. CONCLUSIONS: These results suggest that BFALM may exert antithrombotic activity through inhibition of platelet aggregation via GP IIb/IIIa and thromboxane A(2) pathways, along with anticoagulatory activity through intrinsic and extrinsic pathways.
Subject(s)
Cucurbitaceae/chemistry , Fibrinolytic Agents/pharmacology , Integrin beta3/metabolism , Phytotherapy , Plant Extracts/pharmacology , Platelet Membrane Glycoprotein IIb/metabolism , Pulmonary Embolism/drug therapy , Animals , Blood Coagulation/drug effects , Blood Platelets/chemistry , Blood Platelets/drug effects , Butanols/chemistry , Dose-Response Relationship, Drug , Female , Fibrinogen/metabolism , Fibrinolytic Agents/therapeutic use , Mice , Mice, Inbred ICR , Plant Extracts/chemistry , Platelet Aggregation/drug effects , Pulmonary Embolism/metabolism , Rutin/analysis , Survival Analysis , Thromboxane A2/analysisABSTRACT
OBJECTIVES: The aim of our study is to elucidate whether experimental arterial thrombosis is regulated by physiological doses of androgen and its receptor via modulation of platelet activation. METHODS: Surgical castration was performed in male rats and ferric chloride (FeCl(3)), as a stimulator, induced the experimental arterial thrombosis. Testosterone was measured directly by chemiluminescent immunoassay on the Bayer ADVIA Centaur analyzer. Dihydrotestosterone (DHT) was determined by ELISA using a commercially available kit. A platelet aggregometer was used to assess aggregation, and a platelet adherometer was used to measure adhesion. The contents of TXB(2) and 6-Keto-PGF(1alpha) were assayed by radio-immunoassay using commercially available kits. RESULTS: Our data showed that DHT replaced restored circulating DHT of castrated rats to physiological levels, without being altered by treatment with flutamide. Castration caused significant increases in the thrombus area and weight in castrated rats as compared with control group. In PRP diluted with autologous PPP, ADP-induced platelet aggregation rate was only 9.10%. However, in PRP diluted with Tyrode's buffer, 1 microM ADP-induced platelet aggregation rate rose to 63.65%. In PRP diluted with Tyrode's buffer, and pretreated with DHT (1 nM, 2 nM), ADP-induced platelet aggregation was significantly lowered again. Platelet aggregation in PRP diluted with autologous PPP was enhanced in castrated rats as compared with sham-operated rats, and DHT (2 nM) replacement suppressed platelet aggregation in castrated PRP to the level similar to that of sham-operated rats. However, presence of flutamide (3 microM) significantly increased platelet aggregation in PRP diluted with autologous PPP or Tyrode's buffer. DHT (2 nM) replacement significantly inhibited the ADP-induced platelet adhesion. However, presence of flutamide (3 microM) increased ADP-induced platelet adhesion again. DHT replacement obviously reduced the ratio of TXB(2) to 6-keto-PGF(1alpha) in castrated rats. However, administration of flutamide and DHT to castrated rats caused an increase in the ratio of TxB(2) to 6-keto-PGF1alpha. CONCLUSION: Inhibition of experimental arterial thrombosis by androgen at physiological doses and its receptor is mediated via modulation of platelet activation.
Subject(s)
Androgens/pharmacology , Platelet Activation/drug effects , Platelet Activation/physiology , Receptors, Androgen/physiology , Thrombosis/drug therapy , 6-Ketoprostaglandin F1 alpha/analysis , Androgens/therapeutic use , Animals , Arteries , Castration , Chlorides , Dihydrotestosterone/analysis , Ferric Compounds , Male , Platelet Adhesiveness , Platelet Aggregation , Rats , Testosterone/analysis , Thrombosis/chemically induced , Thromboxane A2/analysisABSTRACT
The aim of the present study was to assess the effect of endogenous male sex hormones on endothelial nitric oxide synthase (eNOS) expression, release and function of the endothelial nitric oxide (NO), as well as to assess the regulatory action of protein kinase C (PKC) on acetylcholine (ACh)-induced endothelial NO release. For this purpose, superior mesenteric arteries from control and orchidectomized male Sprague-Dawley rats were used. eNOS expression and basal-and ACh-induced NO release were similar in arteries from both groups of rats. Orchidectomy decreased the vasodilator effect induced by ACh but did not alter that induced by sodium nitroprusside (SNP). The superoxide anion scavenger, superoxide dismutase (SOD), or the membrane-permeable mimetic of SOD, tempol, only enhanced ACh-induced relaxation in arteries from orchidectomized rats. ACh-induced TXA(2) formation was higher in arteries from orchidectomized than from control rats. Neither the PKC activator, phorbol 12,13-dibutyrate (PDBu), nor the non-selective PKC inhibitor, calphostin C, modified basal- or ACh-induced NO release in arteries from control rats. In arteries from orchidectomized rats, basal- and ACh-induced endothelial NO release were increased by PDBu but decreased by calphostin C. Both Gö6976, a PKC inhibitor that is partially selective for conventional PKC isoforms, as well as PKCzeta pseudosubstrate inhibitor (PKCzeta-PI) decreased both basal- and ACh-induced NO release in arteries from orchidectomized rats. Neither PDBu nor calphostin C modified the vasodilator response induced by ACh in arteries from control rats. In segments from orchidectomized rats, PDBu enhanced the ACh-induced response, but this response was not modified by calphostin C, Gö6976 or PKCzeta-PI. The vasodilator response induced by SNP was not altered by the PKC activators or inhibitors in any artery from either group. These results show that endogenous male sex hormone deprivation does not affect the eNOS expression or the endothelial NO release induced by ACh, but does decrease the vasodilator action of ACh, by increasing NO metabolism and TXA(2) formation. In addition, PKC seems to modulate eNOS activity only in mesenteric arteries from orchidectomized rats, in which conventional and PKCzeta isoforms are involved in the positive regulation of eNOS.
Subject(s)
Mesenteric Arteries/enzymology , Nitric Oxide Synthase Type III/metabolism , Protein Kinase C/metabolism , Acetylcholine/pharmacology , Animals , Blotting, Western/methods , Carbazoles/pharmacology , Dose-Response Relationship, Drug , Enzyme Activation , In Vitro Techniques , Indoles/pharmacology , Male , Naphthalenes/pharmacology , Nitric Oxide/analysis , Nitric Oxide Synthase Type III/analysis , Nitroprusside/pharmacology , Orchiectomy , Phorbol 12,13-Dibutyrate/pharmacology , Protein Kinase C/antagonists & inhibitors , Rats , Rats, Sprague-Dawley , Stimulation, Chemical , Superoxides/metabolism , Thromboxane A2/analysis , Thromboxane A2/metabolism , Vasodilator Agents/pharmacologyABSTRACT
BACKGROUND/AIMS: Thromboxane A2 (TXA2) has been suggested to play a significant role in the development of portal hypertension in fibrosis, and Kupffer cell (KC) derived TXA2 has been shown to mediate the hyperresponsiveness of the portal circulation to the vasoconstrictive actions of endothelin-1 (ET-1) during endotoxemia. The aim of this study was to determine whether the double stresses of prefibrotic changes and endotoxemia additively activate KC to increase release of TXA2 in response to ET-1, resulting in elevated portal resistance. METHODS: One week Bile duct ligation (BDL) rats and sham-operated controls were subjected to isolated liver perfusions following LPS or saline for 6h. In a separate experiment, KC were isolated from BDL or sham rats and incubated with LPS or saline for 6h before the ET-1 treatment. RESULTS: The double stresses of early fibrosis and LPS resulted in a greater sustained increase in portal pressure in response to ET-1 in BDL rats, and this increase correlated well with the much enhanced release of TXA2 in the perfusate. Media from the cultured KC showed significantly greater TXA2 release in response to ET-1 in BDL group than those in sham group, and LPS exacerbated this effect. Protein levels of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2, and thromboxane synthase were also significantly elevated in KC from BDL rats. ET-1 produced a marked increase in cPLA2 activation as measured by the phosphorylation of cPLA2 in KC of both BDL and sham groups. LPS greatly exacerbated the activation of cPLA2. CONCLUSIONS: The data suggest that the double stresses additively activate KC with an upregulation of the key enzymes in the TXA2 biosynthesis and release increased amount of TXA2 via the augmented activation of cPLA2 in response to ET-1, which leads to the increased portal resistance and ultimately hepatic microcirculatory dysfunction.
Subject(s)
Endothelin-1/pharmacology , Hypertension, Portal/etiology , Kupffer Cells/drug effects , Lipopolysaccharides/pharmacology , Liver Cirrhosis, Experimental/etiology , Thromboxane A2/metabolism , Animals , Cyclooxygenase 2/analysis , Cyclooxygenase 2/metabolism , Enzyme Activation , Fibrosis , Group IV Phospholipases A2 , Hypertension, Portal/metabolism , In Vitro Techniques , Kupffer Cells/metabolism , Kupffer Cells/pathology , Liver/blood supply , Liver/drug effects , Liver/pathology , Liver Cirrhosis, Experimental/metabolism , Liver Cirrhosis, Experimental/pathology , Male , Microcirculation/drug effects , Phospholipases A/analysis , Phospholipases A/metabolism , Phospholipases A2 , Phosphorylation/drug effects , Portal Pressure/drug effects , Rats , Rats, Sprague-Dawley , Thromboxane A2/analysisABSTRACT
OBJECTIVE: To assess whether indobufen, a reversible inhibitor of platelet cyclooxygenase (Cox) activity, affects tissue factor (TF) in human monocytes and to investigate the relationship between Cox-derived products and TF. METHODS: TF was evaluated in isolated adherent monocytes, both resting and lipopolysaccharide (LPS)-stimulated, in terms of procoagulant activity, protein, and mRNA levels. The expression of TF surface antigen was determined in LPS-stimulated whole blood monocytes by flow cytometry. The levels of the stable thromboxane A2 (TxA2) metabolite, TxB2, and of prostaglandin E2 (PGE2) were measured in monocyte supernatant by immunoenzymatic techniques. Cox-1 and Cox-2 protein level, tyrosine phosphorylation, and mitogen-activated protein kinase (MAP-kinase) activation were determined by Western blot analysis. RESULTS: Indobufen prevents TF expression and activity both in isolated and in whole blood monocytes. Reduction of TxA2 synthesis, coupled with a lack of effect on PGE2 levels and prevention of ERK1/2 phosphorylation are highlighted as the mechanisms through which indobufen negatively affects TF. CONCLUSIONS: Data show that indobufen down-regulates TF in monocytes. This novel activity, coupled with the antiplatelet effect of the drug, may add benefit for its use in the management of atherothrombosis.
Subject(s)
Cyclooxygenase Inhibitors/pharmacology , Monocytes/metabolism , Phenylbutyrates/pharmacology , Thromboplastin/analysis , Thromboxanes/metabolism , Cells, Cultured , Depression, Chemical , Dinoprostone/metabolism , Flow Cytometry , Humans , Isoindoles , Lipopolysaccharides , Monocytes/drug effects , Thromboplastin/metabolism , Thromboxane A2/analysis , Thromboxane B2/analysisABSTRACT
Prostacyclin (PGI2), a potent vasodilator and inhibitor of platelet aggregation and leukocyte activation, is crucial in vascular diseases such as stroke. Prostacyclin synthase (PGIS) is the key enzyme for PGI2 synthesis. Although expression of PGIS was noted in the brain, its role in ischemic insult remains unclear. Here we reported the temporal and spatial expression of PGIS mRNA and protein after 60-min transient ischemia. Northern blot and in situ hybridization revealed a delayed increase of PGIS mRNA in the ischemic cortex at 24- to 72-h after ischemia; PGIS was detected mainly in the ipsilateral penumbra area, pyriform cortex, hippocampus, and leptomeninges. Western blot and immunohistochemical analysis revealed that PGIS proteins were expressed temporally and spatially similar to PGIS mRNA. PGIS was heavily colocalized with PECAM-1 to endothelial cells at the leptomeninges, large and small vessels, and localized to neuronal cells, largely at the penumbra area. A substantial amount of PGIS was also detected in the macrophage and glial cells. To evaluate its role against ischemic infarct, we overexpressed PGIS by adenoviral gene transfer. When infused 72 h before ischemia (- 72 h), Adv-PGIS reduced infarct volume by approximately 50%. However, it had no effect on infarct volume when infused immediately after ischemia (0 h). Eicosanoid analysis revealed selective elevation of PGI2 at - 72 h while PGI2 and TXB2 were both elevated at 0 h, altering the PGI2/thromboxane A2 (TXA2) ratio from 10 to 4. These findings indicate that PGIS protects the brain by enhancing PGI2 synthesis and creating a favorable PGI2/TXA2 ratio.
Subject(s)
Brain Ischemia/enzymology , Cytochrome P-450 Enzyme System/genetics , Epoprostenol/biosynthesis , Gene Expression Regulation , Intramolecular Oxidoreductases/genetics , Reperfusion Injury/enzymology , Animals , Brain/cytology , Brain/enzymology , Cytochrome P-450 Enzyme System/analysis , Intramolecular Oxidoreductases/analysis , Kinetics , RNA, Messenger , Rats , Thromboxane A2/analysis , Tissue DistributionSubject(s)
Thromboxane A2/analysis , Thromboxane B2/analysis , Asthma/diagnosis , Biomarkers/analysis , Cardiovascular Diseases/diagnosis , Humans , Immunoenzyme Techniques , Ischemia/diagnosis , Kidney Failure, Chronic/diagnosis , Radioimmunoassay , Reference Values , Specimen Handling , Thrombosis/diagnosisABSTRACT
Maturation of big endothelin-1 (big ET-1) commonly produces the 21 amino acid vasoactive ET-1, which binds two ET receptors (ET(A) and ET(B)) to produce its effects. In the guinea pig, the systemic administration of ET-1 produces a bronchoconstrictor response that is mediated indirectly via the release of thromboxane A(2) through ET(B) receptor activation. A new potent metabolite of big ET-1, ET-1 (1-31), has been reported to act as an ET(A) receptor selective agonist. In this study we investigated the effects of ET-1 (1-31), compared with ET-1, on the release of eicosanoids in the isolated and perfused guinea pig lung. We also clarified the implication of ET receptors in these effects using selective ET(A) or ET(B) receptor antagonists, BQ-123 and BQ-788 respectively. Finally, using the neutral endopeptidase 24.11 (NEP 24.11) inhibitor, thiorphan, we determined the involvement of this enzyme on ET-1 (1-31) effects. Infusion of ET-1 (1-31) (50 nM) stimulates a marked release of thromboxane A(2) and prostacyclin equivalent to that observed with a ten times lower concentration of ET-1 (5 nM). BQ-788 (5 nM and 10 nM), but not BQ-123 (1 microM), decreases the release of thromboxane A(2) and prostacyclin triggered by both agonists. Interestingly, thiorphan (25 microM) abolishes the eicosanoid-releasing properties of big ET-1 (100 nM) and ET-1 (1-31). This study demonstrates that ET-1 (1-31) is less potent than ET-1 in stimulating the release of eicosanoids through ET(B) receptor activation in the guinea pig perfused lung. Moreover, the inhibitory properties of thiorphan indicate the possible existence of a bioactive metabolite of ET-1 (1-31). We therefore suggest that NEP 24.11 in the pulmonary vasculature, is implicated in the cleavage of ET-1 (1-31) to produce ET-1 which will further act on both ET receptors.
Subject(s)
Eicosanoids/metabolism , Endothelins/pharmacology , Lung/metabolism , Peptide Fragments/pharmacology , Receptors, Endothelin/metabolism , 6-Ketoprostaglandin F1 alpha/analysis , 6-Ketoprostaglandin F1 alpha/metabolism , Animals , Eicosanoids/analysis , Endothelin Receptor Antagonists , Endothelin-1/pharmacology , Enzyme Inhibitors/pharmacology , Guinea Pigs , Lung/drug effects , Neprilysin/antagonists & inhibitors , Oligopeptides/pharmacology , Peptides, Cyclic/pharmacology , Perfusion , Piperidines/pharmacology , Protein Precursors/pharmacology , Receptor, Endothelin A , Receptor, Endothelin B , Thiorphan/pharmacology , Thromboxane A2/analysis , Thromboxane A2/metabolismABSTRACT
BACKGROUND: The major pathophysiologic changes observed in preeclampsia suggest that endothelial cell dysfunction plays an important role in this disorder. The pathway mediating endothelial cell layer dysfunction is unknown. The concentration of endothelin-1 (ET-1), a potent mammalian vasoconstrictor peptide produced by the vascular endothelium, has been observed to be significantly increased in preeclampsia. In this study, we determined the in vitro effect of endothelin-1 on glutathione and lipid peroxide levels and on the secretion of vasoactive substances by human umbilical vein endothelial cells (HUVECs). METHODS: Human umbilical vein endothelial cells were incubated for 24 h in the presence of different concentrations of ET-1 (0-1000 pmol L(-1)), which were shown in an earlier experiment to have no effects on vitality and proliferation rate of HUVECs. The levels of glutathione (GSH) and lipid peroxides (LPO) were measured in endothelial cell lysates. For the measurement of vasoactive substances, levels of nitric oxide (NO), prostacyclin (PGI2) and thromboxane A2 (TXA2) were measured in endothelial cell supernatants. RESULTS: At lower concentrations (5-50 pmol L(-1)), ET-1 increases the intracellular content of LPO, stimulates the secretion of TXA2, but inhibits the secretion of PGI2 in endothelial cells compared with control cells. At higher concentrations (100-1000 pmol L(-1)), ET-1 increases the intracellular content of GSH, but results in a decrease of LPO, and increase of PGI2, back to control levels. ET-1 has no effect on NO secretion. CONCLUSION: These findings demonstrate that at concentrations corresponding to values in plasma from preeclamptic women, ET-1 induces oxidative stress and results in altered secretion of vasoactive substances in human endothelial cells. We conclude that ET-1 may participate in the pathway leading to endothelial cell dysfunction seen in preeclampsia.
Subject(s)
Endothelin-1/pharmacology , Endothelium, Vascular/metabolism , Glutathione/analysis , Intracellular Fluid/chemistry , Cells, Cultured , Dose-Response Relationship, Drug , Endothelium, Vascular/drug effects , Epoprostenol/analysis , Epoprostenol/metabolism , Female , Humans , Lipid Peroxides/analysis , Nitric Oxide/analysis , Nitric Oxide/metabolism , Pre-Eclampsia/etiology , Pre-Eclampsia/metabolism , Pregnancy , Thromboxane A2/analysis , Thromboxane A2/metabolism , Umbilical VeinsABSTRACT
OBJECTIVES: The hypothesis was tested that CD40-CD154 interaction is involved in the induction of cyclooxygenase-2 and the release of prostanoids in human endothelial cells. METHODS AND RESULTS: In a coculture model of human endothelial cells and a transfected CD154 positive cell line, engagement of CD40 on endothelial cells dramatically increased the synthesis of prostacyclin, prostaglandin E(2) and thromboxane A(2). This upregulation was mediated through an induction of cyclooxygenase-2 (Cox-2), as it was blocked by Cox-2-selective inhibitors. Western blot analysis demonstrated that Cox-2 protein was markedly increased in endothelial cells following CD40 engagement, an effect that was inhibited by pretreatment of cells with an anti-CD154 antibody. CONCLUSION: The data indicate that signaling via CD40 constitutes a major pathway in human endothelial cells for the induction of Cox-2 and release of prostanoids. The CD40-Cox-2 axis thus may represent an important pathway for initiating or maintaining an inflammatory process at the vessel wall.
Subject(s)
CD40 Antigens/metabolism , Dinoprostone/biosynthesis , Endothelium, Vascular/metabolism , Epoprostenol/biosynthesis , Isoenzymes/biosynthesis , Prostaglandin-Endoperoxide Synthases/biosynthesis , Thromboxane A2/biosynthesis , Blotting, Western , CD40 Antigens/pharmacology , Cells, Cultured , Coculture Techniques , Cyclooxygenase 2 , Dinoprostone/analysis , Endothelium, Vascular/cytology , Endothelium, Vascular/immunology , Enzyme Induction , Epoprostenol/analysis , Flow Cytometry , Humans , Inflammation/physiopathology , Membrane Proteins , Probability , Sensitivity and Specificity , Thromboxane A2/analysis , Up-RegulationABSTRACT
The aim of this study was to elucidate the role of thromboxane A(2) (TxA(2)) on asthma-related cough in guinea pigs. Animals were immunosensitized and repeatedly challenged with ovalbumin as an antigen. Coughs were induced by the inhalation of 10(-5) M capsaicin solution for 10 min. Thromboxane synthetase (TxS) inhibitor OKY-046 and thromboxane-receptor antagonist AA-2414 significantly inhibited cough responses in repeatedly challenged animals. Inhalation of TxA(2) mimic STA-2- potentiated cough responses in normal and immunosensitized animals but not in repeatedly challenged ones. Moreover, STA-2-potentiated coughs were inhibited by administration of neurokinin-receptor antagonist FK-224. In repeatedly challenged animals, concentration of TxB(2) in airway lavage fluid, expression of TxS mRNA in tracheal epithelia, and the immunostaining intensity against TxS in mucous cells of the epithelium significantly increased compared with normal and sensitized animals. These results suggest that TxA(2) derived from mucous cells potentiated cough responses to capsaicin in allergic airway inflammation.